The appearance of the Lao Dabear version of Mobocertinib has not only broken the monopoly of high-priced original drugs but has also become a highly anticipated "alternative solution" in the global lung cancer treatment field due to its stable bioequivalence and strict quality control.
How much does the Lao Dabear version of Mobocertinib cost?
The Lao Dabear version of Mobocertinib is available in a specification of 40mg*112 capsules per box, priced at approximately $300. The specific price may be affected by various factors and is subject to the actual selling price.
Important Safety Warnings for Mobocertinib
The use of Mobocertinib requires special attention to the following safety warnings. First, QTc interval prolongation and Torsade de Pointes: Mobocertinib may cause life-threatening QTc interval prolongation and Torsade de Pointes. In clinical studies, 1.2% of patients had QTc interval prolongation exceeding 500 milliseconds, 11% had QTc prolongation greater than 60 milliseconds from baseline, and one patient (0.4%) developed Grade 4 Torsade de Pointes. Monitor electrocardiograms and serum electrolytes regularly before and during treatment. Avoid concomitant use with drugs that prolong the QTc interval or with moderate/strong CYP3A inhibitors. Second, Interstitial Lung Disease (ILD)/Pneumonia: ILD/pneumonia occurred in 4.3% of patients in clinical trials, with 1.2% being fatal. If symptoms such as dyspnea, cough, or fever occur, discontinue the drug immediately and investigate. Permanently discontinue if ILD/pneumonia is confirmed. Third, Cardiac toxicity: Assess cardiac function, including ejection fraction, before and during treatment. Fourth, Diarrhea: Diarrhea may lead to dehydration, electrolyte disturbances, and renal impairment. Use antidiarrheal agents such as loperamide when diarrhea occurs, and replenish fluids and electrolytes. Additionally, animal studies suggest that Mobocertinib has embryo-fetal toxicity. It is contraindicated in pregnant women. Female and male patients of reproductive potential should use effective contraception during treatment and for 1 month after the last dose.
Precautions and Patient Counseling Information for Mobocertinib
What is Mobocertinib? It is a prescription medicine used to treat adult patients with metastatic or unresectable non-small cell lung cancer whose tumors have a specific abnormality (EGFR exon 20 insertion mutation) and whose disease has worsened on or after platinum-based chemotherapy. Important information to tell your healthcare provider before taking: Patients should inform their healthcare provider if they have any heart problems (such as long QT syndrome), electrolyte imbalances (sodium, potassium, calcium, magnesium abnormalities), or other lung diseases. For females of reproductive potential, pregnancy testing should be done before starting treatment. Effective non-hormonal contraception should be used during treatment and for 1 month after the last dose (because hormonal contraceptives such as birth control pills may be less effective). Male patients with female partners of reproductive potential should use effective contraception during treatment and for 1 week after the last dose. Avoid eating grapefruit or drinking grapefruit juice during treatment, as it may increase blood levels of the drug. How to take: Take 160 mg at the same time each day, swallow capsules whole, with or without food. If a dose is missed by more than 6 hours, skip the missed dose. Do not take an extra dose if vomiting occurs. If you experience dizziness, palpitations, difficulty breathing, severe diarrhea, etc., contact your healthcare provider immediately. These are not all the possible side effects. Close monitoring during treatment is required.
